Gnwp nylon membranes

The R-warfarin (≥ 97% pure), L-tryptophan (≥ 98%), HSA (product A1887, from human serum, essentially fatty acid free, ≥ 96%), and D-(+)-glucose (99.5%) and were from Sigma-Aldrich (St. Louis, MO, USA). The chlorpropamide (≥ 99%) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). The Nucleosil Si-300 (pore size, 300 Å; particle size, 7 μm) was acquired from Macherey-Nagel (Duren, Germany). The fructosamine assay was carried out using a kit from Diazyme Laboratories (San Diego, CA, USA). The bicinchoninic acid (BCA) protein assay reagents were acquired from Pierce (Rockford, IL, USA). Water that had been purified by a Milli-Q-Advantage A 10 system (EMD Millipore, Billerica, MA, USA) was used to make all the aqueous solutions and mobile phases that were utilized in this research. These solutions were filtered by passing them through 0.20 μm GNWP nylon membranes from Fisher Scientific (Pittsburgh, PA, USA).

The HSA (lyophilized powder, essentially fatty acid free, ≥ 96% pure), L-tryptophan (≥ 98%), R-warfarin (≥ 97% pure), D- (+)-glucose (99.5%), and sodium azide (>95%) were purchased from Sigma Aldrich (St. Louis, MO, USA). The tolazamide (≥ 99% pure) was from Santa Cruz Biotechnology (Dallas, TX, USA). Modification levels of the in vitro glycated HSA samples were measured using a fructosamine kit purchased from Diazyme Laboratories (San Diego, CA, USA), and the protein content of each chromatographic support was measured using a bicinchoninic acid assay (BCA) from Pierce (Rockford, IL, USA). All aqueous solutions were prepared using purified water from a Milli-Q-Advantage A 10 system (EMD Millipore, Billerica, MA, USA); these solutions were filtrated through 0.20 μm GNWP nylon membranes (Fisher Scientific, Pittsburgh, PA, USA).